Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

B J Kiratli1, S Srinivas, I Perkash

  • 1Spinal Cord Injury Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.

Urology
|February 13, 2001
PubMed
Summary

Androgen deprivation therapy (ADT) for prostate cancer significantly reduces bone density over time. Bone loss is more pronounced with longer ADT duration, surgical castration, and continuous therapy compared to intermittent medical ADT.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Acute Exercise on Cognitive Performance in Active Young Adults: A Randomized Trial Using Online Measures.

Perceptual and motor skills·2026
Same author

EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.

ESMO open·2026
Same author

Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

CTC service heterogeneity and design of a workforce calculator.

Clinical radiology·2023
Same author

Immediate flapless implant placement in a smoker patient: A challenge for optimum aesthetics and secondary stability: A case report.

Nigerian journal of clinical practice·2022

Area of Science:

  • Oncology
  • Endocrinology
  • Bone Metabolism

Background:

  • Androgen deprivation therapy (ADT) is a cornerstone treatment for advanced prostate cancer.
  • Reports suggest an increased risk of osteoporosis and fractures in men undergoing ADT.
  • The longitudinal impact of ADT on bone mineral density (BMD) requires further elucidation.

Purpose of the Study:

  • To assess the long-term effects of androgen deprivation therapy (ADT) on bone mineral density (BMD) in prostate cancer patients.
  • To quantify bone loss associated with increasing duration of ADT.
  • To compare BMD changes between different ADT modalities (surgical vs. medical, continuous vs. intermittent).

Main Methods:

  • Cross-sectional study involving 36 prostate cancer patients.

Related Experiment Videos

  • Dual-energy x-ray absorptiometry (DXA) used to measure hip and spine bone mineral density (BMD).
  • Patients categorized into cohorts based on years of ADT (0, 2, 4, 6, 8, 10 years) and compared to age-matched controls.

    • Main Results:

    • Significant reduction in hip BMD observed in patients on ADT compared to those not on ADT.
    • A clear trend of decreased hip BMD with increasing ADT duration was identified (r = 0.46, P = 0.00008).
    • Bone loss was more severe with surgical castration and continuous ADT, though intermittent therapy showed less bone loss at later time points.

    Conclusions:

    • Increasing duration of androgen deprivation therapy (ADT) is associated with diminished bone mineral density (BMD).
    • Continuous ADT and surgical castration appear more detrimental to bone health than intermittent medical ADT.
    • These findings highlight the importance of monitoring bone health in prostate cancer patients receiving ADT.